drugset / Trial / NCT03170323

Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy

NCT03170323

Phase 4 Unknown 128 enrolled Guangdong Provincial People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Idiopathic membranous nephropathy (IMN) remains a common cause of the nephrotic syndrome in adults. There are few randomized clinical trials regarding the therapeutic effect of mycophenolate mofetil in patients with Idiopathic membranous nephropathy. This study aims to evaluate whether treatment with mycophenolate mofetil is non-inferior to cyclosporins in inducing long-term remission (complete or partial) of proteinuria in patients with idiopathic membranous nephropathy.

Timeline

Start
2018-07-01
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 3 mg/kg
Comparator Cyclosporine Peptide 5 mg/kg
Subject Mycophenolate Mofetil Small molecule 500 mg